摘要
目的统计分析来氟米特与甲氨蝶呤联合治疗强直性脊柱炎的临床效果,探讨来氟米特与甲氨蝶呤联合应用在强直性脊柱炎治疗中的应用价值。方法随机选取2009年12月至2013年5月份我院治疗的171例强直性脊柱炎患者作为研究对象,根据用药方案随机分为观察组86例和对照组85例,对照组患者单纯甲氨蝶呤治疗,观察组患者加用来氟米特,对比分析两组患者的治疗效果以及用药安全性。结果治疗后观察组晨僵时间为(29.11±6.47)min、BASMI为(2.39±1.16)、BASDAI为(2.18±1.31),ESR为(23.84±7.98)mm/h,治疗总有效率88.37%,治疗效果显著优于对照组(P<0.05)。观察组药物不良反应率为17.44%,对照组不良反应发生率为16.47%,无显著性差异(P>0.05)。结论来氟米特与甲氨蝶呤联合治疗能够显著改善强直性脊柱炎治疗效果,提高患者生活质量,是强直性脊柱炎较为理想的治疗方案。
Objective To analyze the clinical curative effect of Leflunomide combined with methotrexate for the treatment of ankylosing spondylitis and discuss the value of Leflunomide combined with methotrexate for the treatment of ankylosing spondylitis. Methods From December 2009 to May 2013, 171 patients with anky- losing spondylitis were selected as the research objects in our hospital. According to the methods of using medicine, they were divided into observation group, n = 86 and control group n = 85. The patients in control group were given methotrexate, and the patients in observation group were given Leflunomide and methotrexate. The treatment effectiveness and safety were compared and analyzed in two groups. Results In observation group, after the treatment, the morning stiffness time was（29.11 ±6.47） mins, BASMI was（2.39 ± 1.16）, BASDAI was （2.18 ± 1.31）, ESR was （23.84 ± 7.98）mm/1 h, the total effective rate was 88.37 %, the treatment results were significantly better than the control group（P 〈 0.05）. In observation group, the drug adverse reaction rate was 17.44 %, the adverse reaction rate in control group was 16.47 %, there were no signifi- cant differences （P 〉 0.05）. Conclusion The I.eflunomide combined with methotrexate for the treatment of ankylosing spondylitis can significantly improve treatment effect and improve the patients＇ quality of life. It is the ideal method for the treatment of ankylosing spondylitis.
出处
《内蒙古医学杂志》
2014年第11期1295-1297,共3页
Inner Mongolia Medical Journal
